Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Nov;119(11):2282-9.
doi: 10.1016/j.ophtha.2012.05.027. Epub 2012 Jul 26.

The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1)

AREDS2 Research Group  1 ; Emily Y Chew, Traci Clemons, John Paul SanGiovanni, Ronald Danis, Amitha Domalpally, Wendy McBee, Robert Sperduto, Frederick L Ferris
Affiliations
Clinical Trial

The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1)

AREDS2 Research Group et al. Ophthalmology. 2012 Nov.

Abstract

Purpose: The Age-Related Eye Disease Study (AREDS) demonstrated beneficial effects of oral supplementation with antioxidant vitamins and minerals on the development of advanced age-related macular degeneration (AMD) in persons with at least intermediate AMD (bilateral large drusen with or without pigment changes). Observational data suggest that other oral nutrient supplements might further reduce the risk of progression to advanced AMD. The primary purpose of the Age-Related Eye Disease Study 2 (AREDS2) is to evaluate the efficacy and safety of lutein plus zeaxanthin (L+Z) and/or ω-3 long-chain polyunsaturated fatty acid (LCPUFA) supplementation in reducing the risk of developing advanced AMD. The study also assesses the reduction in zinc and the omission of β-carotene from original AREDS formulation.

Design: Multicenter, phase III, randomized, controlled clinical trial.

Participants: Persons aged 50 to 85 with bilateral intermediate AMD or advanced AMD in 1 eye.

Methods: All participants were randomly assigned to placebo (n = 1012), L+Z (10 mg/2 mg; n = 1044), ω-3 LCPUFAs (eicosapentaenoic acid + docosahexaenoic acid [650 mg/350 mg]; n = 1069), or the combination of L+Z and ω-3 LCPUFAs (n = 1078). All participants were offered a secondary randomization to 1 of 4 variations of the original AREDS formulation keeping vitamins C (500 mg) and E (400 IU) and copper (2 mg) unchanged while varying zinc and β-carotene as follows: Zinc remains at the original level (80 mg), lower only zinc to 25 mg, omit β-carotene only, or lower zinc to 25 mg and omit β-carotene.

Main outcome measures: Progression to advanced AMD determined by centralized grading of annual fundus photographs.

Results: We enrolled 4203 participants at 82 clinical centers located in the United States. Population characteristics at baseline were as follows: Mean age, 74 years; 57% female; 97% white; 7% current smokers; 19% with prior cardiovascular disease; and 44% and 50% taking statin-class cholesterol-lowering drugs and aspirin, respectively. Ocular characteristics include 59% with bilateral large drusen, 32% with advanced AMD in 1 eye and mean visual acuity of 20/32 in eyes without advanced AMD.

Conclusions: This report presents the AREDS2 study design and the participants' baseline demographic and ocular characteristics.

PubMed Disclaimer

Conflict of interest statement

Financial Interest: A complete list of all AREDS2 investigator financial disclosures, which were collected for regulatory purposes, pursuant to US FDA regulations in 21 CFR Part 54, can be found at www.areds2.org. The member(s) of the writing committee have made the following disclosure(s): Frederick L. Ferris III; Bausch & Lomb (P) and the remainder had no conflicts of interest.

Figures

Figure 1
Figure 1
Age-Related Eye Disease Study 2 (AREDS2) Study Design aDHA and EPA: docosahexanoic acid and eicosapentaneoic acid bAREDS Supplements: vitamins C (500 mg), E (400 international units), beta carotene (15 mg), zinc (oxide 80 mg) and copper (cupric oxide 2 mg) cβ-Carotene: beta-carotene (smokers were randomly assigned to one of these two groups with no beta-carotene in the formulation)
See this image and copyright information in PMC

References

    1. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–485. - PubMed
    1. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–572. - PubMed
    1. Goldman HB, Kiffel S, Weinstock FJ. Cataract surgery and the primary care practitioner. Geriatrics. 2009;64:19–22. 25–26. - PubMed
    1. Eye Diseases Prevalence Research Group. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol. 2004;122:487–494. - PubMed
    1. Age-Related Eye Disease Study Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–1436. - PMC - PubMed

Publication types

MeSH terms